Search clinical trials for: Cetuximab + Paclitaxel

Total 6969 results

Hadassah Medical Organization

Unknown

Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

Breast Neoplasms

Israel
Grupo Español de Tratamiento de Tumores de Cabeza...
Merck Sharp & Dohme LLC; Pivotal S.L.

Terminated

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy (EXTAX)

Head and Neck Cancer
Grupo Español de Tratamiento de Tumores de Cabeza...
Bristol-Myers Squibb; Apices Soluciones S.L.

Active, not recruiting

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) (NIVOTAX)

Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Cancer Stage IV

Spain
University of Chicago
Novartis Pharmaceuticals

Terminated

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

Head and Neck Cancer

United States
Memorial Sloan Kettering Cancer Center
Celgene Corporation; National Comprehensive Cancer Network

Completed

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

HEAD & NECK Cancer

United States
Peking University

Unknown

Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Chemotherapy Effect | Esophageal Cancer, Squamous Cell | Cetuximab Effect

China
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute, Naples

Active, not recruiting

Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer (MITO CERV 2)

Cervical Cancer

Italy
Heidelberg University
Merck KGaA, Darmstadt, Germany

Unknown

Paclitaxel/Carboplatin With or Without Cetuximab in CUP (PACET-CUP)

Carcinoma | Neoplasms, Unknown Primary

Germany
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; National Cheng-Kung... and other collaborators

Completed

A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma

Oral Cancer

Taiwan
Brown University
Bristol-Myers Squibb

Completed

Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer

Gastric Cancer | Esophageal Cancer

United States
Dana-Farber Cancer Institute
Celgene Corporation

Terminated

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck | Basaloid Squamous Cell Carcinoma | Undifferentiated Carcinoma | Adenosquamous Cell Carcinoma
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Esophageal Cancer

Canada, United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Lung Cancer

United States
Northwell Health

Terminated

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell | Carcinoma, Squamous Cell of Head and Neck

United States
State University of New York - Upstate Medical...
CTI BioPharma

Completed

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

Carcinoma, Squamous Cell

United States
Eli Lilly and Company
University of Colorado, Denver; Indiana University; Greenwich Hospital

Completed

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
University of Texas Southwestern Medical Center

Completed

Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
University of Texas Southwestern Medical Center

Completed

Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer (INFIELD)

Head and Neck Cancer | Carcinoma, Squamous Cell | Neoplasms, Oral | Neoplasms, Pharyngeal

United States
University of Texas Southwestern Medical Center

Active, not recruiting

A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer (DARTBOARD)

Head and Neck Cancer

United States
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Eli Lilly and Company

Completed

Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy

Head and Neck Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Refractory Aggressive Non-Hodgkin Lymphoma

United States
University of California, Irvine

Terminated

Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab

Head and Neck Cancer

United States
Washington University School of Medicine
Celgene Corporation

Active, not recruiting

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (CACTUX)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Cancer of the Head and Neck

United States
UNC Lineberger Comprehensive Cancer Center
Celgene Corporation

Completed

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
Shandong Cancer Hospital and Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; RenJi Hospital and other collaborators

Completed

Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma (EXCEL)

Esophageal Cancer

China
University of Maryland, Baltimore
Bristol-Myers Squibb

Completed

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

Cancer of Head and Neck

United States
GlaxoSmithKline

Completed

Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC

Neoplasms, Breast

Japan
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

Head and Neck Cancer | Precancerous Condition

United States
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Taipei Veterans... and other collaborators

Not yet recruiting

A Phase I/II Study of Diffuse Large B-cell Lymphoma (DLBL)

Refractory Diffuse Large B-cell Lymphoma
Washington University School of Medicine
Celgene Corporation

Completed

Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
GlaxoSmithKline

Completed

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Neoplasms, Breast

Poland, Russian Federation, Latvia, Romania
University of Texas Southwestern Medical Center

Completed

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer

Head and Neck Cancer

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Celgene

Active, not recruiting

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Neoplasms

United States, France, Australia, Canada, Italy, Korea, Republic of, Spain, United Kingdom
Eli Lilly and Company

Completed

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States
Jiangsu Cancer Institute & Hospital

Completed

Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

China
Pharmacyclics LLC.

Completed

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Metastatic Renal Cell Carcinoma | Metastatic Colorectal Adenocarcinoma | Advanced Gastric Adenocarcinoma | Advanced Urothelial Carcinoma

United States, Korea, Republic of, Spain, United Kingdom
University Medical Center Groningen
UMC Utrecht; Erasmus Medical Center

Recruiting

Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate (ICON)

Head and Neck Squamous Cell Carcinoma | Margin Assessment

Netherlands
Grupo Español de Tratamiento de Tumores de Cabeza...
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Completed

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Squamous Cell Carcinoma of the Head and Neck

Spain
Charite University, Berlin, Germany

Completed

InductionChemo-Radio-Antibody-Treatment (ICRAT)

Squamous Cell Carcinoma of the Neck | Squamous Cell Carcinoma of the Head

Germany
Amsterdam UMC, location VUmc
Radboud University Medical Center; University Medical Center Groningen

Terminated

Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer (IMPACT-CRC)

Metastatic Colorectal Cancer

Netherlands
Fox Chase Cancer Center
Bristol-Myers Squibb

Completed

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Urologic Neoplasm

United States
West China Hospital
First Affiliated Hospital of Chongqing Medical University

Recruiting

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes (CAPCET)

Colo-rectal Cancer | Capecitabine | Cetuximab

China
Eben Rosenthal
National Cancer Institute (NCI)

Terminated

Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery

Pancreatic Adenocarcinoma

United States
HiberCell, Inc.

Terminated

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer (PRIMUS)

Colorectal Cancer

United States, Puerto Rico, Germany, France
Merck KGaA, Darmstadt, Germany

Completed

Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. (FUTURE)

Previously Untreated Metastatic Colorectal Cancer

France, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
Medical University of Vienna

Recruiting

Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

Head and Neck Squamous Cell Carcinoma

Austria
Arbeitsgemeinschaft medikamentoese Tumortherapie
Merck Sharp & Dohme LLC

Completed

Biomarker Directed Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Austria

Search clinical trials for: Cetuximab + Paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations